Xtant Medical (XTNT) entered into a licensing agreement with Sites Medical for use of OsteoSync™ Ti porous titanium scaffold technology.
OsteoSync Ti is a highly-porous titanium scaffold. Preclinical testing has demonstrated bone attachment strength at nearly 2x that of titanium plasma spray and ~7x that of PEEK material at 5-week follow-up.
XTNT estimates that the total addressable U.S. market for its products that can use OsteoSync Ti is US $2.5BB, with a 5-year CAGR approaching 4.75%.
First products arising from this partnership will be showcased in 4Q17 at NASS. The initiative supports XTNT’s intention to fill portfolio gaps via licensing agreements with strategic partners.
Xtant Medical (XTNT) entered into a licensing agreement with Sites Medical for use of OsteoSync™ Ti porous titanium scaffold technology.
OsteoSync Ti is a highly-porous titanium scaffold. Preclinical testing has demonstrated bone attachment strength at nearly 2x that of titanium plasma spray and ~7x that of PEEK material at 5-week...
Xtant Medical (XTNT) entered into a licensing agreement with Sites Medical for use of OsteoSync™ Ti porous titanium scaffold technology.
OsteoSync Ti is a highly-porous titanium scaffold. Preclinical testing has demonstrated bone attachment strength at nearly 2x that of titanium plasma spray and ~7x that of PEEK material at 5-week follow-up.
XTNT estimates that the total addressable U.S. market for its products that can use OsteoSync Ti is US $2.5BB, with a 5-year CAGR approaching 4.75%.
First products arising from this partnership will be showcased in 4Q17 at NASS. The initiative supports XTNT’s intention to fill portfolio gaps via licensing agreements with strategic partners.
Copy to clipboard 
